Similar articles for PMID: 26112022

1

Cite

Share

PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.

Pérez-Medina C, Tang J, Abdel-Atti D, Hogstad B, Merad M, Fisher EA, Fayad ZA, Lewis JS, Mulder WJ, Reiner T. Pérez-Medina C, et al. J Nucl Med. 2015 Aug;56(8):1272-7. doi: 10.2967/jnumed.115.158956. Epub 2015 Jun 25. J Nucl Med. 2015. PMID: 26112022 Free PMC article.

Cite

Share

2

Cite

Share

In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models.

Pérez-Medina C, Binderup T, Lobatto ME, Tang J, Calcagno C, Giesen L, Wessel CH, Witjes J, Ishino S, Baxter S, Zhao Y, Ramachandran S, Eldib M, Sánchez-Gaytán BL, Robson PM, Bini J, Granada JF, Fish KM, Stroes ES, Duivenvoorden R, Tsimikas S, Lewis JS, Reiner T, Fuster V, Kjær A, Fisher EA, Fayad ZA, Mulder WJ. Pérez-Medina C, et al. JACC Cardiovasc Imaging. 2016 Aug;9(8):950-61. doi: 10.1016/j.jcmg.2016.01.020. Epub 2016 May 25. JACC Cardiovasc Imaging. 2016. PMID: 27236528 Free PMC article.

Cite

Share

3

Cite

Share

An ⁸⁹Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor.

Mason CA, Kossatz S, Carter LM, Pirovano G, Brand C, Guru N, Pérez-Medina C, Lewis JS, Mulder WJM, Reiner T. Mason CA, et al. J Nucl Med. 2020 Mar;61(3):433-436. doi: 10.2967/jnumed.119.230466. Epub 2019 Aug 16. J Nucl Med. 2020. PMID: 31420495 Free PMC article.

Cite

Share

4

Cite

Share

A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting.

Pérez-Medina C, Abdel-Atti D, Zhang Y, Longo VA, Irwin CP, Binderup T, Ruiz-Cabello J, Fayad ZA, Lewis JS, Mulder WJ, Reiner T. Pérez-Medina C, et al. J Nucl Med. 2014 Oct;55(10):1706-11. doi: 10.2967/jnumed.114.141861. Epub 2014 Jul 24. J Nucl Med. 2014. PMID: 25060196 Free PMC article.

Cite

Share

5

Cite

Share

Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.

Rylova SN, Del Pozzo L, Klingeberg C, Tönnesmann R, Illert AL, Meyer PT, Maecke HR, Holland JP. Rylova SN, et al. J Nucl Med. 2016 Jan;57(1):96-102. doi: 10.2967/jnumed.115.162735. Epub 2015 Oct 29. J Nucl Med. 2016. PMID: 26514172 Free article.

Cite

Share

6

Cite

Share

High-Density Lipoprotein Nanobiologics for Precision Medicine.

Mulder WJM, van Leent MMT, Lameijer M, Fisher EA, Fayad ZA, Pérez-Medina C. Mulder WJM, et al. Acc Chem Res. 2018 Jan 16;51(1):127-137. doi: 10.1021/acs.accounts.7b00339. Epub 2017 Dec 27. Acc Chem Res. 2018. PMID: 29281244 Review.

Cite

Share

7

Cite

Share

CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.

Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, Lantto J, Horak ID, Kragh M, Nielsen CH, Kjaer A. Kristensen LK, et al. Theranostics. 2019 Oct 18;9(26):8221-8238. doi: 10.7150/thno.37513. eCollection 2019. Theranostics. 2019. PMID: 31754392 Free PMC article.

Cite

Share

8

Cite

Share

⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.

Mendler CT, Gehring T, Wester HJ, Schwaiger M, Skerra A. Mendler CT, et al. J Nucl Med. 2015 Jul;56(7):1112-8. doi: 10.2967/jnumed.114.149690. Epub 2015 May 21. J Nucl Med. 2015. PMID: 25999431 Free article.

Cite

Share

9

Cite

Share

Light-Induced Radiosynthesis of ⁸⁹Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor.

Klingler S, Fay R, Holland JP. Klingler S, et al. J Nucl Med. 2020 Jul;61(7):1072-1078. doi: 10.2967/jnumed.119.237180. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924725 Free PMC article.

Cite

Share

10

Cite

Share

A generic ⁸⁹Zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography.

Li N, Yu Z, Pham TT, Blower PJ, Yan R. Li N, et al. Int J Nanomedicine. 2017 Apr 20;12:3281-3294. doi: 10.2147/IJN.S134379. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28458546 Free PMC article.

Cite

Share